Abstract

A PROSPECTIVE COMPARISON STUDY ON BEMPEDOIC ACID, EZETIMIBE, AND STATINS AS SECONDARY PREVENTION TO CORONARY ARTERY DISEASE

Aishwarya Jamalpur*, Sai Kiran Jadi*, Ganesh Rathod*, Humayun Baidya* and Dr. D. Venkata Ramana

Abstract

Background: This study is to comprehend the association between LDL cholesterol levels and the drug-of-choice prescribing trends for bempedoic acid, ezetimibe, and statins in CAD patients. The other objectives include categorizing the patients with CAD based on demographics, comorbidities, and BMI, to analyze other parameters - total cholesterol, triglycerides, HDL, and VLDL cholesterol levels in lipid profile test. Methods: A prospective and comparative study was held with a total sample size of 200 cases. These two hundred cases were collected from KIMS Sunshine Hospital, Secunderabad in 6 months. The patients who were diagnosed with CAD and prescribed any of the following drugs: statins, ezetimibe, and bempedoic acid were eligible for the study. Results: Males are more affected than females, and the maximum number of individuals belong to the age group of 51 – 60 years. A lion’s portion of the study sample (69.5%) had abnormal HDL values. In LDL cholesterol levels, the percentage of statins alone and other drugs/combinations (which include Ezetimibe (alone), Bempedoic acid (alone), Statin + Ezetimibe combination, Statin + Bempedoic acid combination, Bempedoic acid + Ezetimibe combination, and Statin + Ezetimibe + Bempedoic acid combination) is 80.5% and 19.5% respectively in optimal levels (190 mg/dl). Conclusion: Coronary artery disease (CAD) patients are prescribed Statins, Ezetimibe, and Bempedoic acid, and their combinations as secondary prevention. This study attests that with the increase in LDL-C levels, the count of prescriptions with statins alone is decreasing, and the count of prescriptions of other drugs/combinations (which include Ezetimibe (alone), Bempedoic acid (alone), Statin + Ezetimibe combination, Statin + Bempedoic acid combination, Bempedoic acid + Ezetimibe combination, and Statin + Ezetimibe + Bempedoic acid combination) is increasing.

Keywords: Coronary Artery Disease, Bempedoic acid, Ezetimibe, Statins.